Path clears for Novartiss Zolgensma after FDA lifts longstanding hold Path clears for Novartis’s Zolgensma after FDA lifts longstanding holdNovartis’s Zolgensma has had a bumpy journey to expanding its access to older patients with spinal muscular atrophy (SMA) with an intrathecal (spinally administered) Published 2 Years Ago by freeamfva
